跳至主要内容
临床试验/NL-OMON22681
NL-OMON22681已完成3 期

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase, a multicenter trial

Sint Maartenskliniek Nijmegen0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - PMR according to the 2012 EULAR/ACR classification criteria - eligibility for treatment with MTX or placebo and show a willingness to follow the study protocol as judged by treating rheumatologist - Signed written informed consent

排除标准

  • - Not being able to speak, read or write Dutch; - PMR-related GC treatment prior to inclusion consisting of either: GC exposure for > 8 weeks, GC treatment with > 30 mg/day, or No further information regarding GC treatment; - Exposure to other systemic immunosuppressant treatments other than GC 3 months prior to inclusion in the study; - Active concomitant GCA or other rheumatic diseases such as RA, spondylarthropathies, connective tissue diseases, or drug-induced myopathies; - Neuropathies or other conditions that might interfere with pain or movement evaluation of PMR, as judged by the treating rheumatologist; - Previous hypersensitivity for prednisolone or MTX.

研究者

发起方
Sint Maartenskliniek Nijmegen

相似试验